Qudexy XR is an extended release formulation of topiramate, an anticonvulsant.
Qudexy XR is specifically indicated as initial monotherapy in patients 10 years of age and older with partial onset or primary generalized tonic-clonic seizures and adjunctive therapy in patients 2 years of age and older with partial onset or primary generalized tonic-clonic seizures and as adjunctive therapy in patients 2 years of age and older with seizures associated with Lennox-Gastaut syndrome.
Qudexy XR is supplied as a capsule for oral administration.
Submit your review
Adverse events associated with the use of Qudexy XR may include, but are not limited to, the following:
difficulty with memory
difficulty with concentration/attention
The recommended dose is as follows: Monotherapy Adults and Pediatric Patients 10 Years and Older with Partial Onset or Primary Generalized Tonic-Clonic Seizures 400 mg orally once daily. Titrate according to the following schedule: Week 1 50 mg once daily Week 2 100 mg once daily Week 3 150 mg once daily Week 4 200 mg once daily Week 5 300 mg once daily Week 6 400 mg once daily Adjunctive Therapy Adults (17 Years of Age and Older) - Partial Onset Seizures, Primary Generalized Tonic-Clonic Seizures, or Lennox-Gastaut Syndrome The recommended total daily dose of Quedexy XR as adjunctive therapy in adults with partial onset seizures or Lennox-Gastaut Syndrome is 200 mg to 400 mg orally once daily. The recommended total dose for adults with primary generalized tonic-clonic seizures is 400 mg orally once daily. Initiate therapy at 25 mg to 50 mg once daily followed by titration to an effective dose in increments of 25 mg to 50 mg every week. Pediatric Patients (Ages 2 Years to 16 Years) - Partial Onset Seizures, Primary Generalized Tonic-Clonic Seizures, or Lennox-Gastaut Syndrome Approximately 5 mg/kg to 9 mg/kg orally once daily. Begin titration at 25 mg once daily (based on a range of 1 mg/kg/day to 3 mg/kg/day) given nightly for the first week. Subsequently, increase the dosage at 1 or 2 week intervals by increments of 1 mg/kg to 3 mg/kg to achieve optimal clinical response. Dose titration should be guided by clinical outcome.